GlassScriptPhysician profile
Peter Digiacomo
NPI 1568493476
$3,947.05
in general payments reported to CMS, 2019-2025
34 companies · $147 in 2025
The $147 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,609 · 2020: $117 · 2021: $227 · 2022: $223 · 2023: $478 · 2024: $145 · 2025: $147.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $771.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $770.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Minerva Surgical, INC | $2,301.23 | 2019-2023 | |
| Abbvie INC. | $307.79 | 2019-2023 | Liletta, Orilissa, Lo Loestrin Fe |
| Gynesonics, INC. | $151.11 | 2021-2022 | |
| Exeltis, USA INC. | $117.41 | 2019-2025 | Slynd |
| Allergan, INC. | $110.07 | 2019-2020 | |
| Channel Medsystems, INC. | $101.48 | 2023 | |
| Millicent US INC | $93.53 | 2024-2025 | Intrarosa, Femring |
| Astellas Pharma US INC | $87.69 | 2023-2025 | Veozah |
| Hologic Sales and Service, LLC | $73.36 | 2019-2022 | |
| Mayne Pharma Commercial LLC | $63.84 | 2023-2025 | |
| Sumitomo Pharma America, INC. | $63.83 | 2023-2024 | Myfembree, Gemtesa |
| Convatec INC. | $50.51 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $40.50 | 2022-2023 | |
| Avion Pharmaceuticals | $29.53 | 2019 | |
| Myovant Sciences INC. | $28.79 | 2021-2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertical Pharmaceuticals, LLC | $27.86 | 2019 | |
| Therapeuticsmd, INC. | $26.00 | 2019-2020 | |
| Coopersurgical, INC. | $25.42 | 2021-2022 | |
| Lupin INC. | $22.31 | 2020 | |
| Mylan Pharmaceuticals INC. | $19.98 | 2022 | |
| Sanofi Pasteur INC. | $17.99 | 2024 | |
| Axonics, INC. | $17.21 | 2024 | Bulkamid, Axonics |
| Agile Therapeutics, INC. | $16.58 | 2022 | |
| Evofem Biosciences, INC. | $16.33 | 2021 | |
| Sage Therapeutics, LLC | $16.19 | 2023 | |
| Avanos Medical | $15.15 | 2021 | |
| Organon LLC | $15.09 | 2024 | |
| Daiichi Sankyo INC. | $14.47 | 2022 | |
| Pfizer INC. | $13.66 | 2025 | |
| Becton, Dickinson and Company | $13.09 | 2019 | |
| Mission Pharmacal Company | $12.61 | 2020 | |
| Cumberland Pharmaceuticals, INC. | $12.57 | 2019 | |
| Roche Diagnostics Corporation | $12.15 | 2019 | |
| Amag Pharmaceuticals, INC. | $11.72 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Digiacomo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.